You are here » News

News

Entries for 2007

December 06, 2007

Paris (France) and Lausanne (Switzerland), 6 December 2007 - Ipsen (Euronext: FR0010259150; IPN), an innovation-driven, international specialty pharmaceutical group, and Galderma, a leading global pharmaceutical company focused on dermatology, today announced that they have entered into a new partnership for the exclusive promotion and distribution of Ipsen's Dysport®, the company's botulinum toxin type A product, for use in aesthetic medicine and dermatological indications in Brazil, Argentina and Paraguay.

Read more...

Posted in: Press release

July 17, 2007

Fort Worth, TX – July 17, 2007 – Galderma Laboratories, L.P. has published the second edition of the Galderma Quality Report for Dermatology & Managed Care. This insightful report is provided complimentary as an educational service of Galderma, a leading worldwide dermatology company, as a follow-up to the inaugural Quality Report issued in 2005.

Read more...

Posted in: Press release

June 20, 2007

Fort Worth, Texas, June 20, 2007 /PRNewswire/ - Galderma Laboratories, L.P., announced today that the U.S. Food and Drug Administration (FDA) has approved Differin(R) (adapalene) Gel, 0.3%, a new, higher concentration formulation of Differin(R) (adapalene) 0.1%, a topical retinoid indicated for the treatment of acne. Differin(R) Gel, 0.3% provides physicians with a more potent formulation of adapalene that is efficacious enough to treat moderate to moderately-severe acne while still providing a favorable side effect profile. Differin(R) Gel, 0.3% will be available by prescription by July 2007.

Read more...

Posted in: Press release

June 07, 2007

The Galderma Global Corporate Campaign won the Medical Marketing Association's 2007 International Award of Excellence (IN-AWE) Competition in the Photography category.

Read more...

Posted in: Press release

February 26, 2007

Paris (France) and Lausanne (Switzerland), 26 February 2007 - Ipsen grants Galderma exclusive rights to develop, promote and distribute its botulinum toxin type A product for aesthetic indications in Europe and certain other territories.

Read more...

Posted in: Press release

 1 / 2  

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read

Video

We are committed

See all videos